Cingulate

Cingulate EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Cingulate (CING) as of Nov 21, 2026 is -4.64. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -4.07 — a change of 14.05% (lower).

EV/OCF

-4.64

YoY

14.05%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Cingulate is 2025 -4.64 . EV/OCF (Enterprise Value to Operating Cash Flow) of Cingulate was 2024 -4.07 . It decreases by 14.05% lower compared to the previous year.

The Cingulate EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
-8.79 USD
Jan 1, 2020
-12.19 USD
Jan 1, 2021
-6.41 USD
Jan 1, 2022
-5.20 USD
Jan 1, 2023
-5.69 USD
Jan 1, 2024
-4.07 USD
Jan 1, 2025
-4.64 USD
The Cingulate EV/OCF history
YEAREV/OCFYoY
-4.64+14.05%
-4.07-28.58%
-5.69+9.41%
-5.20-18.76%
-6.41-47.43%
-12.19+38.61%
-8.79—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Cingulate is -4.64 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Cingulate changed from -4.07 to -4.64, representing a 14.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Cingulate since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cingulate

All Key Metrics — Cingulate